GET DAILY SIGNALSWhat Cardiff Oncology (CRDF) Investors Should Watch Ahead of Q3 2026 Results
Key Takeaways
- Cardiff Oncology (CRDF) is expected to report third-quarter 2026 results in early November, with Wall Street consensus projecting a net loss of roughly $0.14 to $0.16 per share.
- Analysts model minimal royalty revenue near $80,000 for the period, reflecting the company's pre-commercial, clinical-stage profile.
- Investors are watching the company's cash runway closely, given that management has signaled it will need additional capital to fund the planned CRDF-005 Phase 3 registrational study.
- The lead program, onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), remains the central catalyst after a successful End-of-Phase 2 meeting with the FDA earlier in 2026.
- For more on the latest company developments, visit the Major News page, track Today's Price Move, review analyst Price Targets, and explore the Forecast pages.
- Looking for additional trading ideas? Explore Trending AI Robots to see AI-driven strategies currently drawing market attention.
Earnings Context and Why It Matters
For a clinical-stage biotechnology company such as Cardiff Oncology, quarterly earnings are less about revenue and more about capital discipline and clinical execution. The company generates only modest royalty income from assets unrelated to its lead drug candidate, so investors focus on operating-expense trends, the cash balance, and progress toward pivotal clinical milestones. Prior quarters have shown a narrowing net loss as research and development (R&D) spending declined following the completion of the randomized Phase 2 CRDF-004 trial. With a Phase 3 registrational study now on the horizon, this report offers a timely window into how management is balancing spending against a runway that currently extends into 2027.
Earnings Expectations
Consensus estimates for Cardiff Oncology's third quarter of 2026 point to a net loss of approximately $0.14 per share, with individual analyst projections ranging from about $0.13 to $0.20 per share. Royalty revenue is expected to remain minimal, with estimates clustering near $80,000. By comparison, the company reported a net loss of $0.14 per share in the second quarter of 2026, beating the consensus estimate of $0.16, on revenue of roughly $104,000. In the first quarter of 2026, the net loss was $0.18 per share on revenue of $41,000, coming in below expectations. Investors will be watching whether the downward trend in R&D spending continues and whether management provides updated guidance on the timing and cost of the planned Phase 3 trial. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into Cardiff Oncology's third-quarter print centers on clinical progress rather than financial performance. The stock has historically reacted to data milestones — most notably the positive update from the randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated mCRC — more than to the modest earnings miss or beat. In April 2026, the company announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), during which it aligned on key design elements for a Phase 3 registrational trial. Key risk factors heading into the report include the timing and cost of that pivotal study, potential dilution from future capital raises, and any changes to the cash-runway guidance. Investors will also listen for updates on investigator-initiated studies across other cancer indications.
Forward Outlook and Key Factors to Monitor
The most important forward-looking item is the design and initiation of the CRDF-005 Phase 3 registrational study for onvansertib in first-line RAS-mutated mCRC. Management has said it plans to share additional Phase 3 details and its regulatory strategy, and any update on trial timelines, sites, or enrollment plans could meaningfully shape investor expectations.
Capital allocation is another central theme. The company ended the first quarter of 2026 with approximately $46.1 million in cash, cash equivalents, and short-term investments, and subsequently completed a financing that management indicated would extend the runway into the third quarter of 2027. Because the Phase 3 program will require additional capital, investors should monitor operating-expense trends and any commentary on future funding needs.
Finally, watch for data catalysts beyond the lead program. Updated CRDF-004 results presented at major oncology meetings, along with preclinical work combining onvansertib with antibody-drug conjugates and ongoing investigator-initiated trials in pancreatic, lung, and breast cancers, could broaden the company's clinical narrative. Operating-expense discipline and clinical execution will likely remain the key drivers of investor sentiment in the quarters ahead.
Exploring AI-Powered Research Tools
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter biotech names by technical patterns, fundamentals, and AI signals. It helps surface comparable setups and trend data that might otherwise take hours to compile manually, giving a clearer picture of where CRDF stands relative to peers before earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRDF in +2.91% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRDF advanced for three days, in 208 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CRDF's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where CRDF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
CRDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CRDF turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
CRDF moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDF crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CRDF entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.215) is normal, around the industry mean (2.788). P/E Ratio (-1.259) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (178.571) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology
Advertisement